C. Boni

22.3k total citations · 6 hit papers
122 papers, 13.9k citations indexed

About

C. Boni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C. Boni has authored 122 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 67 papers in Pulmonary and Respiratory Medicine and 34 papers in Cancer Research. Recurrent topics in C. Boni's work include Colorectal Cancer Treatments and Studies (45 papers), Cancer Treatment and Pharmacology (45 papers) and Gastric Cancer Management and Outcomes (24 papers). C. Boni is often cited by papers focused on Colorectal Cancer Treatments and Studies (45 papers), Cancer Treatment and Pharmacology (45 papers) and Gastric Cancer Management and Outcomes (24 papers). C. Boni collaborates with scholars based in Italy, France and Spain. C. Boni's co-authors include Aimery de Gramont, Josep Tabernero, Thierry André, Tamas Hickish, C. Topham, Matilde Navarro, Philip R. Clingan, John Bridgewater, Andrea Bonetti and Marta Zaninelli and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

C. Boni

119 papers receiving 13.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

2000 3.0k citations Aimery de Gramont, Arié Figer et al. Journal of Clinical Oncology profile →
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

2004 2.7k citations Thierry André, C. Boni et al. New England Journal of Medicine profile →
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

2009 1.6k citations Thierry André, C. Boni et al. Journal of Clinical Oncology profile →
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

2006 1.5k citations Eric Van Cutsem, Vladimir Moiseyenko et al. Journal of Clinical Oncology profile →
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

2002 739 citations Giorgio V. Scagliotti, Filippo de Marinis et al. Journal of Clinical Oncology profile →
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

2014 720 citations Fotios Loupakis, Chiara Cremolini et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by C. Boni

Since Specialization

Citations

This map shows the geographic impact of C. Boni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Boni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Boni more than expected).

Fields of papers citing papers by C. Boni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Boni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Boni. The network helps show where C. Boni may publish in the future.

Co-authorship network of co-authors of C. Boni

This figure shows the co-authorship network connecting the top 25 collaborators of C. Boni. A scholar is included among the top collaborators of C. Boni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Boni. C. Boni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association with programmed death ligand-1 (PDL-1) expression and Helicobacter Pylori infection in patients with non-diffuse type gastric carcinoma 2015 ·Annals of Oncology ·Maria Di Bartolomeo, Alessandro Pellegrinelli, Roberto Iacovelli, Filippo Pietrantonio, Rosa Berenato, M. Caporale, Monica Niger, Maria Aurelia Barbera, Roberto Labianca, (unknown), Gerardo Rosati, Donato Nitti, C. Boni, D. Amadori, Maurizio Cantore, Filippo de Braud, Emilio Bajetta	2
2	Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study 2014 ·Annals of Oncology ·Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, (unknown), Simon Hitier, P. Rougier	88
3	Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells 2014 ·Lung Cancer ·(unknown), Maria Cecilia Mengoli, Alessandra Bisagni, Maria Banzi, C. Boni, Giulio Rossi	55
4	A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma 2013 ·The Oncologist ·Lorenza Rimassa, Tiziana Pressiani, C. Boni, Carlo Carnaghi, Elena Rota Caremoli, S. Fagiuoli, Paolo Foa, Stefania Salvagni, Enrico Cortesi, Maria Chiara Tronconi, Nicola Personeni, Silvia Bozzarelli, Maria Banzi, Silvia Fanello, Romano Fabio Lutman, Laura Giordano, Armando Santoro	29
5	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 2013 ·Digestive and Liver Disease ·Stefano Cascinu, Rossana Berardi, Alberto F. Sobrero, Paolo Bidoli, Roberto Labianca, Salvatore Siena, Daris Ferrari, Sandro Barni, Enrico Aitini, Vittorina Zagonel, Francesco Caprioni, Federica Villa, Stefania Mosconi, Luca Faloppi, Giuseppe Tonini, C. Boni, Pierfranco Conté, Francesco Di Costanzo, Michela Cinquini	41
6	Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono 2013 ·Annals of Oncology ·Lisa Salvatore, Gianluca Masi, Fotios Loupakis, Chiara Cremolini, Marta Schirripa, Lorenzo Fornaro, Cristina Granetto, (unknown), Francesco Di Costanzo, Lorenzo Antonuzzo, Lorenzo Marcucci, Samanta Cupini, C. Boni, Maria Banzi, Silvana Chiara, (unknown), C. Valsuani, Andrea Bonetti, Luca Boni, Alfredo Falcone	2
7	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST) 2012 ·British Journal of Cancer ·C. Boni, Marcello Tiseo, Luca Boni, Editta Baldini, F. Recchia, Carlo Barone, Francesco Grossi, Domenico Germano, Elide Matano, Giovanni Marini, Roberto Labianca, Francesco Di Costanzo, (unknown), (unknown), C. Caroti, Manlio Mencoboni, Francesca Zanelli, Tiziana Prochilo, Mara A. Cafferata, Andrea Ardizzoni	19
8	Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. 2010 ·Journal of Clinical Oncology ·Luís Teixeira, Tamas Hickish, Christophe Tournigand, (unknown), Andrea Bonetti, Francisca Rivera, C. Boni, Josep Tabernero, Thierry André, Aimery de Gramont	5
9	The Role of Cetuximab in Pre-Treated Refractory Patients with Metastatic Colorectal Cancer: Outcome Study in Clinical Practice 2008 ·Journal of Chemotherapy ·G. Lelli, (unknown), (unknown), Benedetta Urbini, Francesco Bonetti, (unknown), Guido Biasco, Maria A. Pantaleo, Alba A. Brandes, C. Calandri, (unknown), Oriana Nanni, C. Boni, Maria Banzi, Francesca Negri, (unknown), Francesca Di Fabio, D. Turci	4
10	A3-05: Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen 2007 ·Journal of Thoracic Oncology ·Rodryg Ramlau, Jaafar Bennouna, Eng Huat Tan, Bonne Biesma, Armando Santoro, C. Boni, Helmut Klein, (unknown), Ricard Mesı́a, (unknown)	0
11	Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer breakdown → 2004 ·New England Journal of Medicine ·Thierry André, C. Boni, (unknown), Matilde Navarro, Josep Tabernero, Tamas Hickish, C. Topham, Marta Zaninelli, Philip R. Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery de Gramont	2694
12	Ifosfamide in Non-Small Cell Lung Cancer 2003 ·Oncology ·C. Boni, Francesca Zanelli	6
13	Phase II Study of Taxol Combined With Ifosfamide and Carboplatin in the Treatment of Stage IIIb–IV Non-Small-Cell Lung Cancer 2003 ·American Journal of Clinical Oncology ·Alberto Zaniboni, Andrea Ardizzoni, Filippo de Marinis, L Portalone, C. Boni, Fausto Meriggi, Mara A. Cafferata, (unknown), Valter Torri, (unknown), Riccardo Rosso	6
14	Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer 2003 ·Oncogene ·Rafael Rosell, Giorgio V. Scagliotti, Kathleen D. Danenberg, Reginald V. Lord, Gerold Bepler, Silvia Novello, J. Cooc, Lucio Crinò, José Javier Sánchez, Miquel Tarón, C. Boni, Filippo de Marinis, Maurizio Tonato, M. Marangolo, F Gozzelino, (unknown), Monica Rinaldi, Dennis Salonga, Craig Stephens	164
15	Randomized trial comparing cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma 2002 ·Cancer ·Giorgio Cocconi, (unknown), C. Boni, Giancarlo Bisagni, Guido Ceci, Ermanno Rondini, Mariangela Bella, (unknown), Luisa Savoldi, Roberta Camisa, Paolo Bruzzi	6
16	Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer breakdown → 2000 ·Journal of Clinical Oncology ·Aimery de Gramont, Arié Figer, Michel Seymour, M. Homerin, Abdel Hmissi, Jim Cassidy, C. Boni, H. Cortés-Funes, Andrés Cervantes, Gilles Freyer, D. Papamichael, N Le Bail, Christophe Louvet, Daniel Hendler, Filippo de Braud, C. Wilson, F. Morvan, Andrea Bonetti	3040
17	High-Dose Folinic Acid and 5-Fluorouracil Alone or Combined With Hydroxyurea in Advanced Colorectal Cancer 1998 ·American Journal of Clinical Oncology ·Francesco Di Costanzo, Silvia Gasperoni, P Malacarne, (unknown), Gabriele Luppi, (unknown), (unknown), (unknown), Rodolfo Passalacqua, F. Figoli, R Algeri, S. Zironi, (unknown), C. Boni	9
18	Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC) 1998 ·European Journal of Cancer ·C. Boni, Luisa Savoldi, Giancarlo Bisagni, Guido Ceci, Lucio Crinò, Vincenzo De Lisi, Francesco Di Costanzo, Laura Lasagni, (unknown), Gabriella Moretti, Ermanno Rondini, M. Sassi, (unknown)	2
19	Original article: Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC) 1992 ·Annals of Oncology ·Francesco Di Costanzo, Roberta Bartolucci, F. Calabresi, Maria Sofra, (unknown), (unknown), C. Boni, M. Bacchi	44
20	Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial 1989 ·Cancer ·C. Boni, Giorgio Cocconi, Giancarlo Bisagni, Guido Ceci, (unknown)	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact